Gene | Criteria for selection for gene panel | Hot spot | Frequency of mutation in PCD | Frequency of mutation in present study | % | Total number of cases | PCD type |
---|---|---|---|---|---|---|---|
KRAS | Potentially druggable | Exon 2;3 | Up to 30% | 24 | 24% | 22 | MM |
NRAS | Potentially druggable | Exon 2;3 | Up to 30% | 14 | 16% | 14 | MM |
DIS3 | Prognosis | Whole gene | Up to 1% | 14 | 12% | 11 | MM MGUS |
TENT5C (FAM46C) | Prognosis | Whole gene | Up to 4% | 13 | 12% | 11 | MM MGUS |
TP53 | Prognosis | Whole gene | Up to 20% | 9 | 10% | 9 | MM |
BRAF | Potentially druggable | Exon 11; 15 | Up to 9% in rr MM* | 9 | 10% | 9 | MM |
TRAF3 | Frequently mutated | Whole gene | Up to 4% | 8 | 7% | 6 | MM |
FGFR3 | Prognosis/potentially druggable | Whole | Up to 1.5% | 4 | 6% | 4 | MM |
IDH1 | Potentially druggable | Exon 4 | Â | 3 | 3% | 3 | MM ALA |
EGR1 | Frequently mutated | Whole gene | Up to 1% | 2 | 2% | 2 | MM |
IRF4 | Prognosis | Exon 3 | Up to 3% | 2 | 2% | 2 | MM |
CCND1 | Prognosis/potentially druggable | Whole gene | Up to 3% | 0 | no | 0 | no |
PRDM1 | Frequently mutated | Whole gene | Up to | 0 | no | 0 | no |
IDH2 | Potentially druggable | Exon 4 | Â | 0 | no | 0 | no |